Project
A multicenter, randomized, double-blind, parallel-group,placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312)in patients with secondary progressive multiple sclerosis
Completed ยท 2014 until 2016
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Status
Completed
Start Date
2014
End Date
2016
Financing
Industry
Study Design
A multicenter, randomized, double-blind, parallel-group,
placebo-controlled